Public procurement notice: Contract Award Notice
Published: 2019-09-13
Buyer: NHS Central London Clinical Commissioning Group
Country: UK
Contract type: Services
Procedure: Negotiated without a prior call for competition
CPV classification: 85100000: Health services
Estimated value: 5000000 GBP

Technical requirements: Provision of a new pilot person-centred Type 2 diabetes intensive lifestyle service involving clinically-sound interventions supported by life-style change programmes and intensive facilitation to reduce medication dependency to achieve remission or partial remission.
Provision of a new pilot person-centred Type 2 diabetes intensive lifestyle service involving clinically-sound interventions supported by life-style change programmes and intensive facilitation to reduce medication dependency to achieve remission or partial remission. The service will provide and manage a healthcare campaign to encourage and support people across NW London with Type 2 diabetes to complete a course consisting of either a very low calorie diet (VLCD)/or a low carbohydrate diet in order to achieve significant health improvement and corresponding reduction in costs and medicines. The service will run for an initial 3-year duration from October 2019 until October 2022, with rights reserved for this to be extended for a further 2 years (5 years maximum) until October 2024.
The service is to mobilise and scale up to pilot a new approach to intervention, considered critical to deliver an innovative programme of healthcare intervention. The contract will involve significant financial risk being borne by the service provider, with payments being linked to achievement of successful service outcomes and staged payments deferred until April 2020.
Recognising its obligations and responsibilities under the NHS (Procurement Patient Choice and Competition)(No 2) Regulations 2013, the contracting authority has assessed this provider to be the only technically capable provider, able to mobilise and scale up to pilot a new approach to intervention, having the expert track record and experience considered critical to deliver this innovative programme of healthcare intervention. The contract will involve significant risk being borne by the provider, with payments being linked to achievement of successful service outcomes, with staged payments. Throughout Q1 of the 2019/202 financial year the contracting authority presented the remission service concept to a number of its current and potential providers/suppliers. Market research was completed through a series of meetings, presentations and some cost-modelling workshops. The service specification was benchmarked against supplier capabilities and the ROI for the local health economy. As a consequence the risk-share/gain-share model proved unattractive to the providers/suppliers given that they would carry all the up-front operational costs and the return would be in the form of verified but deferred medicines savings. The provider being awarded the contract is the only organisation accepting the risks and able to technically deliver a viable service to meet the specified requirements of the contracting authority in terms of pace, approach and affordability.
The contract is being directly awarded to a single provider assessed to be the only organisation with sufficient appropriate capability to deliver at pace and scale this innovative healthcare intervention service.


Winner: Independent Clinical Services Ltd
Award value: 5000000
Number of bids: 1